Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents

INTRODUCTION: The treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) continues to evolve. Sipuleucel-T was the first immunotherapy approved by the US Food and Drug Administration (FDA) to treat asymptomatic or minimally symptomatic mCRPC. The androgen receptor-targeting...

Descripción completa

Detalles Bibliográficos
Autores principales: Hafron, Jason M., Wilfehrt, Helen M., Ferro, Christine, Harmon, Matt, Flanders, Scott C., McKay, Rana R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123060/
https://www.ncbi.nlm.nih.gov/pubmed/35352309
http://dx.doi.org/10.1007/s12325-022-02085-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123060/
https://www.ncbi.nlm.nih.gov/pubmed/35352309
http://dx.doi.org/10.1007/s12325-022-02085-6

Ejemplares similares